DelveInsight’s, “Androgenetic Alopecia Pipeline Insight 2023” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Androgenetic Alopecia pipeline landscape. It covers the Androgenetic Alopecia pipeline drug profiles, including Androgenetic Alopecia clinical trials and nonclinical stage products. It also covers the Androgenetic Alopecia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the Androgenetic Alopecia Pipeline treatment landscape of the report, click here @ Androgenetic Alopecia Pipeline Outlook
Key Takeaways from the Androgenetic Alopecia Pipeline Report
For further information, refer to the detailed Androgenetic Alopecia Unmet Needs, Androgenetic Alopecia Market Drivers, and Androgenetic Alopecia Market Barriers, click here for Androgenetic Alopecia Ongoing Clinical Trial Analysis
Androgenetic Alopecia Overview
Androgenetic alopecia is a common form of hair loss in both men and women. In men, this condition is also known as male-pattern baldness. Hair is lost in a well-defined pattern, beginning above both temples. Over time, the hairline recedes to form a characteristic “”M”” shape. Pattern or androgenetic alopecia is a genetically predetermined disorder due to excessive response to androgens which affects up to 50% of males and females.
Request a sample and discover the recent advances in Androgenetic Alopecia Ongoing Clinical Trial Analysis and Medications, click here @ Androgenetic Alopecia Treatment Landscape
Androgenetic Alopecia Emerging Drugs
KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. For the AGA indication, on 8 September 2021, Kintor Pharma announced that the primary endpoint of the phase II clinical trial of KX-826 on adult male patients was met, as results showed good efficacy and safety profile. On 11 July 2021, Kintor Pharma announced that the Food and Drug Administration of the United States greenlighted KX-826’s phase II clinical trial for AGA to be conducted in the United States.
Clascoterone solution 7.5% is a novel AR inhibitor that targets androgen receptors in the scalp and is currently being studied for the treatment of androgenetic alopecia (AGA). Clascoterone solution 7.5% acts by inhibiting DHT’s binding with androgen receptors in scalp hair follicles and thus may interfere with DHT’s effect on scalp hair loss. A Phase II dose ranging study with clascoterone solution in males ended in early 2019. Clascoterone solution 7.5% was selected as the best candidate for the Phase III adult male AGA program. A Phase II study involving female AGA subjects is underway with top-line results expected 3Q 2021.
Dive deep into rich insights for drugs for Androgenetic Alopecia Market Drivers and Androgenetic Alopecia Market Barriers, click here @ Androgenetic Alopecia Unmet Needs and Analyst Views
Androgenetic Alopecia Pipeline Therapeutics Assessment
There are approx. 12+ Androgenetic Alopecia companies which are developing the Androgenetic Alopecia therapies. The Androgenetic Alopecia companies which have their Androgenetic Alopecia drug candidates in the most advanced stage, i.e. Phase II include, Kintor Pharma.
Androgenetic Alopecia Pipeline Segmentation
DelveInsight’s Androgenetic Alopecia pipeline report covers around 12+ products under different phases of clinical development like
Androgenetic Alopecia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Androgenetic Alopecia Products have been categorized under various Molecule types such as
Androgenetic Alopecia Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Scope of the Androgenetic Alopecia Pipeline Report
Got Queries? Find out the related information on Androgenetic Alopecia Mergers and acquisitions, Androgenetic Alopecia Licensing Activities @ Androgenetic Alopecia Emerging Drugs, and Recent Trends
Table of Content
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting-services